Patently-O

FEBRUARY 24, 2022

The Supreme Court has not yet granted writ of certiorari in any patent cases this term. The request, known as a CVSG, typically requires four of the nine Justices — the same number needed to grant certiorari. But, the real boost only happens if the government brief supports certiorari. Genentech, Inc. ,

Patent Law 95

Patent Law Law Patent Litigation 95

Patently-O

SEPTEMBER 26, 2022

A quick recap: Despite dozens of interesting and important cases, the Supreme Court denied all petitions for writ of certiorari for the 2021-2022 term. Bottom line, no patent cases were decided by the Court in the 2021-2022 term and none were granted certiorari for the new term starting this week. by Dennis Crouch.

Patent Law 125

Patent Law Law Patent Invention 125

Patently-O

NOVEMBER 11, 2022

As reported in posts by Dennis and Jason , the Supreme Court recently granted certiorari in Amgen v. A few days later, on November 7, the Supreme Court denied certiorari in Juno v. Amgen’s successful petition for certiorari relies heavily on Death , and its authors filed an amici curiae brief in support of Amgen’s petition.

Inventor 48

Inventor Invention Patent Reporting 48

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Introduction. 2021 saw several important milestones in the biosimilars space, including the much anticipated first interchangeable designations by FDA and the approval of the first ophthalmology biosimilar. The biosimilar market also exhibited continued growth, with multiple biosimilar developers reporting strong sales of biosimilars through 2021.

Litigation 52

Litigation Settlement Patent Marketing 52